Discover Trends & Challenges Impacting the Industry
Genezen is excited to share our latest industry report, which reveals crucial insights into the evolving landscape of cell and gene therapy reimbursement. Gain a deeper understanding of the financial and regulatory dynamics shaping the future of advanced therapies.
Key Insights Include:
- 70% of respondents say CGT reimbursement is more complex than traditional therapies.
- 52% of companies have adjusted their development strategies due to reimbursement challenges.
- 42% of companies found that reimbursement negotiations didn’t align with investor expectations.
Access the Free Report
Navigating reimbursement is critical for ensuring patient access and commercial success. This exclusive report provides actionable insights to help you make informed decisions in an increasingly complex reimbursement environment.
Meet Genezen at ASGCT | Booth #1027
Join us at ASGCT 2025 to connect with our experts and learn how Genezen is advancing viral vector manufacturing. Stop by our booth for an exclusive opportunity to discuss your therapy development needs.
Our team will be available for one-on-one conversations to explore how we can accelerate your program’s transition from early-stage development to commercialization.
